How ePRO technology simplified patient data capture for IPF trials

Breaking down barriers in lung nodule diagnosis, Olympus is successfully reaching patients with the key information needed in an often-confusing process. Our very own Dr. Thomas Gildea joined BlackDoctor.org to discuss our ongoing partnership with the American Lung Association, the communication gap in lung nodule diagnosis, and how education is critical for patient care. Read more in his full interview! #OlympusPost https://bit.ly/47ILhBD

Breaking down barriers in lung nodule diagnosis, Olympus is successfully reaching patients with the key information needed in an often-confusing process. Our very own Dr. Thomas Gildea joined BlackDoctor.org to discuss our ongoing partnership with the American Lung Association, the communication gap in lung nodule diagnosis, and how education is critical for patient care. Read more in his full interview! #OlympusPost https://bit.ly/42Wep6L

Breaking down barriers in lung nodule diagnosis, Olympus is successfully reaching patients with the key information needed in an often-confusing process. Our very own Dr. Thomas Gildea joined BlackDoctor.org to discuss our ongoing partnership with the American Lung Association, the communication gap in lung nodule diagnosis, and how education is critical for patient care. Read more in his full interview! #OlympusPost https://bit.ly/4hLOLYr

Breaking down barriers in lung nodule diagnosis, Olympus is successfully reaching patients with the key information needed in an often-confusing process. Our very own Dr. Thomas Gildea joined BlackDoctor.org to discuss our ongoing partnership with the American Lung Association, the communication gap in lung nodule diagnosis, and how education is critical for patient care. Read more in his full interview! #OlympusPost https://bit.ly/4i3BI4Q

Breaking down barriers in lung nodule diagnosis, Olympus is successfully reaching patients with the key information needed in an often-confusing process. Our very own Dr. Thomas Gildea joined BlackDoctor.org to discuss our ongoing partnership with the American Lung Association, the communication gap in lung nodule diagnosis, and how education is critical for patient care. Read more in his full interview! #OlympusPost https://bit.ly/4ooz4c8

Why cough and cough monitoring, and why now? 👇 Read our key insights from #ERS2025 at EMJ - highlighting the latest objective cough monitoring technologies (Strados Labs, C-mo Medical Solutions, Hyfe, Vitalograph, SIVA Health), insights from scientific presentations on optimal cough monitoring duration, cough statistics, cough bouts, and applications of cough monitoring as signals of efficacy and tolerability. A timely throwback to last month’s European Respiratory Society's 2025 meeting! #DigitalBiomarker #Cough

Objective cough monitoring has come a long way. In addition to Hyfe, there are now multiple platforms demonstrating >90% sensitivity against human annotation and strong inter-rater reliability across respiratory conditions. The field is converging on a pragmatic 7-day monitoring standard that captures day-to-day variability while remaining operationally feasible, with validated algorithms now enabling fully automated analysis and privacy-preserving designs addressing IRB concerns. Additionally, PPG-based wear detection delivers 99% adherence verification, eliminating reliance on patient self-report and supporting rigorous per-protocol analysis. Basically, objective cough monitoring is now operationally viable as a primary (or secondary) endpoint in respiratory drug trials, offering pharma sponsors a quantifiable, continuous alternative to subjective patient-reported outcomes. Huge progress from just a few years ago when reliable cough monitoring was basically impossible.

In precision health, clinically meaningful parameters are quantified to individualise therapies and track response. Cough, one of the most common reasons for seeking care and a key respiratory sign, has historically been hard to measure reliably: 24-hour ‘snapshots’ are noisy, day-to-day variability is high, and manual annotation is slow, inconsistent, and privacy-intrusive. The ERS Congress 2025 highlighted how continuous, largely automated, and privacy-preserving technologies now enable objective, at-scale cough measurement suitable for clinical research and care.

With the global prevalence of Parkinson’s disease rising rapidly, there is a growing urgency to improve how symptoms are monitored and treatment decisions are made. Our latest white paper presents a pioneering clinical investigation into the use of electromyography and motion-based technology for therapy path classification in Parkinson’s care. The study examines how combining objective sensor data with patient-reported information can improve clinical evaluations and support more informed therapy decisions. Read our latest white paper: https://lnkd.in/dEzWfere #parkinsons #emg #whitepaper #clinicalinvestigation

Finnish health-tech startup, Adamant Health (founded 2020), aims to revolutionize treatment outcomes of Parkinson’s disease with personalized data-driven disease management. Read their recent paper on clinical investigation. #codedtoconnect #braininnovation #Finnishinnovation #innovation #personalizedcare #diseasemonitoring #brainhealth #Parkinsonsdisease